• Achieved electrical readout of quantum states in its carbon-based qubit materials
• Validated device design and manufacturing approach through reproducible performance
• Expanded partnerships to accelerate quantum technology development

During the half year period, Archer delivered technical and commercial progress across its quantum and Biochip platforms. The company achieved key breakthroughs in quantum readout for its proprietary carbon qubit materials, including the successful on-chip electrical detection of spin states for its EDMR device and showing gating in its SET architecture, validating a scalable and semiconductor-compatible pathway toward practical quantum devices. Archer also advanced material scalability, device reproducibility, and TMR sensing performance under cryogenic temperatures as part of the 12CQ quantum project. The company expanded strategic collaborations with Emergence Quantum and CSIRO to accelerate commercial translation and open potential new revenue streams, including with quantum machine learning. For the Biochip program, Archer delivered clinically aligned accuracy in potassium sensing in human blood and strengthened its dual-platform strategy of silicon and graphene with promising results that support scalable manufacturing. Looking ahead, Archer is focused on integrating these advances into functional prototypes, improving operating performance, and progressing toward clinical trial readiness for the Biochip and targeted qubit demonstration in 2026.

The company has a strong cash position of $10.3 million as of 31 December 2025 to fund its R&D and commercialisation activities.

Archer is focused on integrating its technical and commercial advances into functional prototypes, improving operating performance, and progressing toward clinical trial readiness for the Biochip and targeted qubit demonstration in 2026. The company will also commence discussions with global commercial partners to expedite potential commercialisation.